GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges

Ashok K. Shetty, Dinesh Upadhya

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Diminution in the number of gamma-amino butyric acid positive (GABA-ergic) interneurons and their axon terminals, and/or alterations in functional inhibition are conspicuous brain alterations believed to contribute to the persistence of seizures in acquired epilepsies such as temporal lobe epilepsy. This has steered a perception that replacement of lost GABA-ergic interneurons would improve inhibitory synaptic neurotransmission in the epileptic brain region and thereby reduce the occurrence of seizures. Indeed, studies using animal prototypes have reported that grafting of GABA-ergic progenitors derived from multiple sources into epileptic regions can reduce seizures. This review deliberates recent advances, limitations and challenges concerning the development of GABA-ergic cell therapy for epilepsy. The efficacy and limitations of grafts of primary GABA-ergic progenitors from the embryonic lateral ganglionic eminence and medial ganglionic eminence (MGE), neural stem/progenitor cells expanded from MGE, and MGE-like progenitors generated from human pluripotent stem cells for alleviating seizures and co-morbidities of epilepsy are conferred. Additional studies required for possible clinical application of GABA-ergic cell therapy for epilepsy are also summarized.

Original languageEnglish
Pages (from-to)35-47
Number of pages13
JournalNeuroscience and Biobehavioral Reviews
Volume62
DOIs
Publication statusPublished - 01-03-2016

Fingerprint

Cell- and Tissue-Based Therapy
gamma-Aminobutyric Acid
Epilepsy
Median Eminence
Seizures
Interneurons
Pluripotent Stem Cells
Butyric Acid
Neural Stem Cells
Temporal Lobe Epilepsy
Presynaptic Terminals
Brain
Synaptic Transmission
Stem Cells
Morbidity
Transplants

All Science Journal Classification (ASJC) codes

  • Neuropsychology and Physiological Psychology
  • Cognitive Neuroscience
  • Behavioral Neuroscience

Cite this

@article{21d50eddb9ac4466ab3c06bc929cb848,
title = "GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges",
abstract = "Diminution in the number of gamma-amino butyric acid positive (GABA-ergic) interneurons and their axon terminals, and/or alterations in functional inhibition are conspicuous brain alterations believed to contribute to the persistence of seizures in acquired epilepsies such as temporal lobe epilepsy. This has steered a perception that replacement of lost GABA-ergic interneurons would improve inhibitory synaptic neurotransmission in the epileptic brain region and thereby reduce the occurrence of seizures. Indeed, studies using animal prototypes have reported that grafting of GABA-ergic progenitors derived from multiple sources into epileptic regions can reduce seizures. This review deliberates recent advances, limitations and challenges concerning the development of GABA-ergic cell therapy for epilepsy. The efficacy and limitations of grafts of primary GABA-ergic progenitors from the embryonic lateral ganglionic eminence and medial ganglionic eminence (MGE), neural stem/progenitor cells expanded from MGE, and MGE-like progenitors generated from human pluripotent stem cells for alleviating seizures and co-morbidities of epilepsy are conferred. Additional studies required for possible clinical application of GABA-ergic cell therapy for epilepsy are also summarized.",
author = "Shetty, {Ashok K.} and Dinesh Upadhya",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.neubiorev.2015.12.014",
language = "English",
volume = "62",
pages = "35--47",
journal = "Neuroscience and Biobehavioral Reviews",
issn = "0149-7634",
publisher = "Elsevier Limited",

}

GABA-ergic cell therapy for epilepsy : Advances, limitations and challenges. / Shetty, Ashok K.; Upadhya, Dinesh.

In: Neuroscience and Biobehavioral Reviews, Vol. 62, 01.03.2016, p. 35-47.

Research output: Contribution to journalReview article

TY - JOUR

T1 - GABA-ergic cell therapy for epilepsy

T2 - Advances, limitations and challenges

AU - Shetty, Ashok K.

AU - Upadhya, Dinesh

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Diminution in the number of gamma-amino butyric acid positive (GABA-ergic) interneurons and their axon terminals, and/or alterations in functional inhibition are conspicuous brain alterations believed to contribute to the persistence of seizures in acquired epilepsies such as temporal lobe epilepsy. This has steered a perception that replacement of lost GABA-ergic interneurons would improve inhibitory synaptic neurotransmission in the epileptic brain region and thereby reduce the occurrence of seizures. Indeed, studies using animal prototypes have reported that grafting of GABA-ergic progenitors derived from multiple sources into epileptic regions can reduce seizures. This review deliberates recent advances, limitations and challenges concerning the development of GABA-ergic cell therapy for epilepsy. The efficacy and limitations of grafts of primary GABA-ergic progenitors from the embryonic lateral ganglionic eminence and medial ganglionic eminence (MGE), neural stem/progenitor cells expanded from MGE, and MGE-like progenitors generated from human pluripotent stem cells for alleviating seizures and co-morbidities of epilepsy are conferred. Additional studies required for possible clinical application of GABA-ergic cell therapy for epilepsy are also summarized.

AB - Diminution in the number of gamma-amino butyric acid positive (GABA-ergic) interneurons and their axon terminals, and/or alterations in functional inhibition are conspicuous brain alterations believed to contribute to the persistence of seizures in acquired epilepsies such as temporal lobe epilepsy. This has steered a perception that replacement of lost GABA-ergic interneurons would improve inhibitory synaptic neurotransmission in the epileptic brain region and thereby reduce the occurrence of seizures. Indeed, studies using animal prototypes have reported that grafting of GABA-ergic progenitors derived from multiple sources into epileptic regions can reduce seizures. This review deliberates recent advances, limitations and challenges concerning the development of GABA-ergic cell therapy for epilepsy. The efficacy and limitations of grafts of primary GABA-ergic progenitors from the embryonic lateral ganglionic eminence and medial ganglionic eminence (MGE), neural stem/progenitor cells expanded from MGE, and MGE-like progenitors generated from human pluripotent stem cells for alleviating seizures and co-morbidities of epilepsy are conferred. Additional studies required for possible clinical application of GABA-ergic cell therapy for epilepsy are also summarized.

UR - http://www.scopus.com/inward/record.url?scp=84953897124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953897124&partnerID=8YFLogxK

U2 - 10.1016/j.neubiorev.2015.12.014

DO - 10.1016/j.neubiorev.2015.12.014

M3 - Review article

C2 - 26748379

AN - SCOPUS:84953897124

VL - 62

SP - 35

EP - 47

JO - Neuroscience and Biobehavioral Reviews

JF - Neuroscience and Biobehavioral Reviews

SN - 0149-7634

ER -